🔗 Share this article

As the US undertakes sweeping adjustments to its vaccine guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the pandemic and has zeroed in on potential deaths after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Program

Public health authorities had intended to announce major changes to the childhood immunization program in December, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of step with much of the global community with insufficient data for public health gain. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some childhood immunization guidelines in the US so as to align more like Denmark, a society with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Background

Dr. Høeg has little discernible background in medication creation, approval processes or administrative roles, which has been customary for former directors of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Previous directors of the center would “grasp legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who led the center have had.”

CDER has an immense portfolio at the agency, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic program approves numerous generic drugs. There is also a biosimilars division, over-the-counter program and more, and every single one have to be managed,” she explained. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the position, which oversees more than 5,000 staff members. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Response and Controversial Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries are based on inaccurate assumptions”.

“Her resume matches the responsibilities of her role,” the representative said, noting the period Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who takes the calls?” Howard asked. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards laxer rules of most medications, aside from immunizations.”

Documented History on Vaccines

With immunizations, Høeg has a clearer, if problematic, history, some experts observe. She published a research paper using non-validated crowd-sourced reports to determine the rate of heart inflammation following Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new government included altering rules for new vaccines and halting “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested excluding young men from receiving Covid vaccines.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to accommodate the science in a extremely disingenuous, dishonest way,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|